MedMira Inc.

As of April 30, 2026, MedMira Inc. carries a market capitalization of 38.60M, placing it among publicly traded companies globally. Its enterprise value stands at 48.43M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of April 30, 2026, MedMira Inc. has 701.73M shares outstanding.

These figures are as of April 30, 2026. The price-to-sales ratio is 104.00, and the price-to-book ratio stands at -1.57.

These figures are as of April 30, 2026. The EV/Sales ratio of 130.68 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 48.43M versus a market cap of 38.60M, with the gap driven by net debt and cash on the balance sheet.

As of April 30, 2026, MedMira Inc. maintains a current ratio of 0.06, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -40.10, indicating conservative leverage, while an interest coverage ratio of -1.62 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended April 30, 2026. Return on assets (ROA) is negative at -83.46, reflecting losses generated across the asset base. Inventory turnover of 0.49 indicates how many times MedMira Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 1, 2026, MedMira Inc.'s stock has declined approximately 23.53% over the past 52 weeks. The 50-day moving average sits at 0.06, while the 200-day moving average is 0.08.

Over the twelve months ended April 30, 2026, MedMira Inc. generated 370,568.00 in revenue and converted that into -2.99M in net income, yielding earnings per share of 0.00. EBITDA reached -1.67M, while operating income came in at -1.97M.

As of April 30, 2026, MedMira Inc. holds - - in cash and equivalents against 9.83M in total debt, resulting in a net debt position of 7.58M. Total book value stands at -24.52M, with working capital of -23.85M providing operational flexibility.

MedMira Inc. produced -1.19M in operating cash flow over the twelve months ended April 30, 2026. After subtracting - - in capital expenditures, free cash flow totaled -1.19M - equivalent to 0.00 per share.

Over the twelve months ended April 30, 2026, MedMira Inc. posted a gross margin of 72.39, reflecting its pricing power and cost economics. The operating margin of -531.16 and net profit margin of -808.18 provide insight into operational efficiency.

These figures cover the twelve months ended April 30, 2026. Free cash flow yield is negative at -3.09: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -3.04, meaning MedMira Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of April 30, 2026, MedMira Inc. has an Altman Z-Score of -53.75, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.